Journal of Pharmacy and Pharmacology 10 (2022) 316-329
doi: 10.17265/2328-2150/2022.12.002

What the Drugs Does to the Body: Pharmacodynamics

Gudisa Bereda

Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia

Abstract: Pharmacokinetics, which includes the kinetics of absorption, distribution, biotransformation/metabolism, and excretion, may be described as the study of the dynamic motions of foreign substances (xenobiotics) throughout their passage through the body. Absorption is the process through which a medicine enters the systemic circulation after being administered, for example, as a pill or capsule. Based on the characteristics of the substance and the method of administration, bioavailability is the portion of the first delivered medication that enters the systemic circulation. What is meant by "distribution" is how a material spreads throughout the body. The molecular characteristics of the medicine and the physiology of the patient taking it may influence the distribution variety. A medication may be protein-bound or free in the body. Only free drugs are able to pass into other fluid compartments, function at their pharmacologically active locations like receptors, or be eliminated. Metabolism is the process through which the body converts a medication into other substances. The process by which a substance is expelled from the body is known as excretion. The term "half-life" ($t_{1/2}$) refers to the amount of time it takes for the body to remove half of the initial dose of a medication. The substance is deemed undetectable and unable to have a pharmacodynamic impact after three to five half-lives.

Key words: Absorption, Body, Distribution, Drugs, Excretion, Metabolism, Pharmacokinetics.

Abbreviations

ATP	Adenosine triphosphate
Cyp450	Cytochrome P450
L/ADME	Liberation/absorption, distribution, metabolism and excretion
CL	Clearance
K_e	Elimination rate constant
PDC	Plasma drug concentration
Pgp	P-glycoprotein
PK	Pharmacokinetics
$T_{1/2}$	Half-life
Vd	Volume of distribution

1. Introduction

The terms pharmakon, which means "drug", and kinetikos, which means "moving or setting in motion" are the roots of the phrase "pharmacokinetics" [1]. Pharmacokinetics, which is defined as the movement of a drug into, through, and out of the body during the course of its absorption, bioavailability, distribution, metabolism, and excretion, is sometimes stated as what the body does to a medication. The study of a drug's and/or its metabolite's kinetics in the body is known as pharmacokinetics (PK). The transient changes that a medication and its metabolites undergo in serum, plasma, whole blood, tissue target, and target organs over time are known as pharmacokinetics. A medication passes through a number of processes as it is absorbed, transported throughout the body, metabolized, and/or excreted (ADME) (Figure 1) [2]. The body is a tremendously complicated system. Pharmacokinetics is also known as the study of the dynamic movements of foreign chemicals (also known as xenobiotics) during their passage through the body. As a result, it includes the kinetics of absorption, distribution, metabolism, and excretion. It is also sometimes referred to as the body's response to xenobiotics [3-5].

A medicine's pharmacokinetics can be determined by both chemical characteristics of the drug and variables specific to the patient. Predicting the pharmacokinetic parameters in populations may be done by using specific patient-related characteristics,

Corresponding author: Gudisa Bereda, B.pharm, MPH fellow, research field: pharmacy. Email: gudisabareda95@gmail.com.

This article is a preprint and has not been certified by peer review

such as renal function, genetic make-up, sex, and age. For instance, in senior patients, the half-life of several medications, especially those that need both metabolism and excretion, may be considerably prolonged. Most definitely, physiologic changes that come with aging have an impact on certain pharmacokinetic characteristics, and the other components are connected to each person's physiology. It is possible to forecast the consequences of some individual variables (such as renal failure, obesity, hepatic failure, and dehydration), while other factors are idiosyncratic and as a result have unexpected effects. Due to individual variances, medication administration must be based on each patient's needs and empirical dose adjustments until the therapeutic goal is achieved. Due to its potential to delay an ideal response or trigger negative effects, this strategy is frequently insufficient [6]. Therapeutic medicine monitoring is the use of pharmacokinetic principles to customize medication. The intrinsic pharmacological characteristics of a medicine at its site of action determine the sort of reaction that individual has to it. The rate and extent of drug intake from the site of administration, the rate and extent of drug distribution to different tissues, including the site of action, and the rate of drug elimination from the body are just a few examples of factors that frequently affect the speed of onset, the intensity, and the duration of the response [7, 8]. Pharmacokinetics has an impact on a medication's determined method of administration, dosage and frequency, and dosing intervals [9]. To become safe, usable, and effective therapies, potential medications must have the correct pharmacokinetic qualities. A drug must enter the bloodstream (absorption), travel to the site of action (distribution), remain unchanged long enough to have a therapeutic effect before being converted to safe metabolites (metabolism), and be sufficiently excreted (excretion) in order to have a "good" pharmacokinetic profile (Figure 2) [10, 11]. Absorption and disposal are the two main study categories that comprise pharmacokinetics. The migration of medications from the place of application to various bodily fluids is known as disposition. The study of distribution and elimination is a more specific subclassification of disposition. Elimination refers to both metabolism and excretion [12].

and has not been certified by peer review



Fig. 1 Principles of ADME.



Fig. 2 Schematic representation of the absorption, distribution, metabolism and excretion of medicines.

2. Absorption

Absorption is the process through which a medicine enters the systemic circulation after being administered, for example, as a pill or capsule. Absorption affects how quickly and how concentratedly a medication may reach the desired site of action, such as plasma. In most cases, freedom is also a part of the absorption process. The process by which a drug is liberated from its pharmacological dosage form is referred to as liberation [13]. Ionization state, molecular weight, solubility, and formulation are all aspects that are connected to medicine. Drugs that are small, nonionized, and lipid-soluble penetrate plasma membranes the fastest. Small compounds frequently travel across membranes during the absorption process by passive transport, but more frequently by use of proteins known as drug transporters [14]. Depending on the method of delivery (by mouth, feeding tube, or rectal suppository in the GI tract), absorption may be enteral or parenteral (not in the GI tract, such as an injection or topical medication). Blood flow to the region of absorption, GI motility, and the drug's formulation (immediate release vs. prolonged release) are other variables that may impact the amount of the drug absorbed (for enteral medications). Drug absorption is influenced by a number of variables, including method of administration, drug formulation, chemical makeup, and interactions with food. X-rays cause vasoconstriction, which decreases medication absorption; in contrast, parasympathetic stimulation increases drug absorption by loosening the smooth muscle in blood vessels. Females have slower gastric emptying times than males, mostly due to estrogen's actions [15]. The bioavailability of a medicine is influenced by the method of delivery (for instance, oral, intravenous, and inhalation), which determines how much of the drug's active form actually reaches the circulation and its intended target location. When a medication is administered intravenously, there is no requirement for absorption, and bioavailability is 100% since the drug's active form is directly transported to the systemic circulation. However, oral medicines only partially absorb their contents and deliver fewer drugs to the site of action. For instance, before entering the systemic circulation, a number of medications taken orally are processed in the liver or the gut wall. First-pass metabolism is what causes a reduction in the absorption of medications [16]. The molecular weight, topological polar surface area, solubility, ionization, and other physicochemical qualities of a medicine may all have an impact on how well it is absorbed. After oral absorption, the first-pass impact (among other variables) will ultimately determine bioavailability [17]. Drugs that are absorbed through the skin or bodily fluids will diffuse through biological membrane barriers into the

This article is a preprint and has not been certified by p
view

circulation. When a medicine has to penetrate the blood-brain barrier, neuronal membranes, renal tubular cells, or hepatocytes, it can be transported either passively across the concentration gradient, which is the initial transport route, or actively, which requires energy like ATP. Only drugs that are free and unionized may pass through cell membranes. A number of factors, including irregular gastrointestinal motility, illnesses of the stomach, small and large intestines, GI infections, radiation, and interactions with other substances in the GIT, such as food, may influence the amount or rate of medication absorption [18]. To be absorbed, disseminated, and removed, drugs must pass through a multitude of obstacles.

3. The Main Way Drugs are Absorbed

Passive diffusion: The capacity of the drug to dissolve into the barrier between the two compartments, the thickness of the barrier, and the gradient in drug concentration between the two adjacent compartments are all factors that affect passive diffusion. Lipid membranes are frequently used as these barriers. Therefore, passive drug transfer will be influenced by the level of ionization and the lipid solubility [19].

Active transport: A very extensive family of transporters collectively referred to as ATP binding cassette transporters may facilitate active transport (or ABC transporters). Adenosine triphosphate (ATP) is the energy source used by these transporters to move drug molecules across biological membranes. The active transport system has several important characteristics, including saturability, structural selectivity, and ATP dependency [20].

Saturability: Saturability carriers typically show a concentration beyond which no increase in movement occurs, in contrast to passive diffusion.

Structural selectivity: Transporters with varied degrees of structural selectivity for pharmaceuticals and endogenous compounds are said to have structural selectivity. Structural selectivity can be highlighted as a crucial drug interaction strategy since structurally similar compounds would fight for binding to these transporters.

ATP Dependence: The capacity to transport medications against a concentration gradient is what is meant by ATP dependency. Multidrug resistance transporters (MDR transporters), such as P-glycoprotein, are examples of the ATP binding cassette category of transporters (Pgp, MDR1 or ABCB1). P-glycoprotein is an efflux transporter, which means it moves drugs from inside the cell and into the extracellular environment. P-glycoprotein is produced in the blood-brain barrier and the gut, among other places. P-glycoprotein is important for both medication interactions and pharmacokinetics. P-glycoprotein substrates are pushed back into the intestinal lumen in the gut, which reduces their absorption after they diffuse into intestinal epithelial cells. P-glycoprotein substrates that diffuse into these cells may be carried back out into the circulation, preventing further penetration into the brain. P-glycoprotein substrates are more readily absorbed when P-glycoprotein-inhibiting medications are used. P-glycoprotein substrate absorption is decreased by substances or illness conditions that cause P-glycoprotein [21].

Facilitated transport: Another vast family of transporters known as the human solute-linked carrier (SLC) family mediates facilitated transfer. The only difference between this category of transporters and the ABC transporters is that they do not immediately bind and hydrolyze ATP as a source of energy. The organic ion transporter in the renal tubules, which is in charge of synthesising certain diuretics into the renal tubule, their site of action, is an example of facilitated transport [22].

Drug properties: A drug's pharmacokinetics can be significantly impacted by its broad chemical characteristics. A drug must be released from its formulation, dissolve in aqueous solutions, and be able to pass through several hydrophobic barriers (for

This article is a preprint and has not been certified by peer review

instance, the plasma membrane) in order to be absorbed and distributed to its site of action or its site of removal [23].

Drug formulations: To release the medication, solid formulations (such as pills, capsules, and suppositories) must dissolve. In rare circumstances, the dose form may become compromised by disintegration (example, dry mouth caused by aging, disease, or concomitant medicine management sluggishness dissolution of nitroglycerin tablets). However, some medications may be specifically designed to allow disintegration only in certain portions of the gastrointestinal tract (for instance, enteric-coated tablets disintegrate in the small intestine), with the goal of protecting the medication from being destroyed by stomach acid (for instance, erythromycin), or to protect the stomach from a drug that is irritant (example, enteric-coated aspirin). In order to extend the duration of action of medications, tablets and capsules can also be designed with controlled-release, extended-release, or sustained-release dosage forms. Particularly beneficial for medications with relatively short half-lives are sustained-release versions [24-26].

Drug chemistry: The capacity of a medicine to cross biological membranes, dissolve and travel in biological fluids will depend on its physical and chemical qualities. Smaller molecules are absorbed more quickly because of their size and structure. Drugs with similar structural similarities may compete with one another for these binding sites, which may affect their pharmacokinetics [27].

State of ionization: The nonionized version of medications is more lipids permeable and may thus diffuse past biological barriers more effectively. The pH at which the medication will be evenly distributed between the ionized and nonionized forms is indicated by the drug's pKa property. An indicator of lipid solubility is the lipid-water partition coefficient. Drugs will pass across biological membranes more quickly if they have larger lipid-water partition coefficients [28].

Effect of pH: Since most medications are weak acids or bases, they dissociate into ionized and nonionized forms to variable degrees in solution. The drug's pKa and the pH of the solution in which it is dissolved will be used to determine the distribution between ionized and nonionized forms [29]. Men and women have different stomach fluids; male gastric fluid is more acidic than female gastric fluid (pH = 1.92, pH = 2.59 respectively), and men have a larger baseline and maximal flow of gastric fluid and acid release than women (lowered by 30% during pregnancy). Lowered pH sequences result in greater uptake of weak bases and decreased uptake of weak acids. Weak acids are more readily ionized under basic conditions. Weak acids are more readily nonionized under acidic conditions. Clinical applications for the ideas of basic and acidic medications and their relative ionization at various pH levels are possible. For instance, urine acidification is used to increase the clearance of amphetamine, a common drug with a pKa of around 9.8. Making the urine acidic increases the quantity of amphetamine in the ionized form, which prevents the drug from being reabsorbed into the circulation. Positively, urine alkalinization is used to increase the excretion of the acidic medication ASA. The amount of the medication in the ionized form increases by around 10,000 times when the pH of urine is raised above the pKa of ASA. The drug's ionized form cannot be reabsorbed into the circulation through the renal tubule [29].

Drug interactions (Figure 3), variations in drug distribution or elimination, variations in a person's ability to metabolize and eliminate the drug (for instance, genetics), disease states (for instance, renal or hepatic impairment), or physiologic states (for instance, extremes of age or obesity), that affect a drug's absorption, distribution, or elimination. When the following are true, therapeutic monitoring utilizing drug concentration data is beneficial.

1) There is a strong correlation between plasma concentration and the pharmacologic response.

This article is a preprint and has not been certified by peer review

The magnitude of the pharmacologic effects should increase with plasma concentration throughout at least a small concentration range;

2) Significant variations in plasma drug concentrations among subjects following a single dosage;
3) The medication's therapeutic window is small (such that, the therapeutic concentration is close to the toxic concentration);
4) Other straightforward methods cannot be used to swiftly establish the drug's desired pharmacologic effects (example, blood pressure measurement for antihypertensives).

When:

a) There is no clearly defined therapeutic plasma concentration range, the utility of therapeutic drug monitoring is constrained;
b) Unless metabolite concentrations are also carefully considered, the synthesis of pharmacologically active metabolites of a medication makes it difficult to apply data on plasma drug concentration to clinical consequences;
c) Both surprisingly low drug concentrations and large concentrations of the medication may cause toxic consequences;
d) Too high or too low amounts don't seem to have any significant consequences [30].



Fig. 3 Process for reaching dosage decisions with therapeutic drug monitoring.

4. Bioavailability

Based on the characteristics of the substance and the method of administration, bioavailability is the portion of the first delivered medication that enters the systemic circulation. Also directly related to drug absorption is bioavailability. For instance, 100% of the medicine is nearly quickly absorbed into the bloodstream when it is administered intravenously, resulting in 100% bioavailability [30]. Pharmaceuticals can be produced as a salt, crystal solution, liposomes, liquid, oil, tablet, gel, or capsule, or they can be designed for sustained or prolonged release. Drug formulation, stability in the GI tract, characteristics of the drug for absorption and biotransformation, individual physiology and pathology, such as GI pH, GI motility, blood perfusion, bacterial flora, malabsorption states, kidney, liver, and cardiac roles, and genetics are all factors that affect bioavailability. Orally delivered

This article is ... fied by peer review

medications are subject to first-pass liver metabolism, which reduces their bioavailability. Drugs given intravenously or parenterally will skip the liver's first-pass metabolism and have a 100% bioavailability in the bloodstream. Because blood perfusion at the muscle site of injection affects drug absorption, intramuscular administration of a medicine does not ensure a high percentage of drug bioavailability [31].

5. Distribution

The term "distribution" refers to how a drug is distributed throughout the body. Both the molecular properties of the drug and the physiology of the patient taking it affect its distribution. Diffusion and convection are two major processes that may have an impact on the distribution. These two variables may be influenced by the drug's polarity, size, or binding properties, the patient's fluid balance (hydration and protein concentrations), or the person's body type. The distribution's goal is to reach the so-called effective medication concentration. This is the drug's concentration at the receptor location where it was intended to bind. A medicine must not be protein-bound in order to be active and must reach the prescribed compartmental destination, as indicated by the volume of distribution. In comparison to males, women have lower body weights and BMIs; a higher percentage of body fat; a larger plasma volume, albeit this amount fluctuates during the menstrual cycle and during pregnancy; and a higher rate of organ blood flow in women than in men. In general, males have larger red blood cell volumes than women do in terms of total body water, extracellular water, intracellular water, total blood volume, and plasma volume. The increased total body water, plasma volume, extracellular water, and intracellular water will elevate the volume of distribution, reducing drug concentration, if an average male and an average female are exposed to the same dosage of a water soluble medication. In women, for example, ethanol has a lower volume of distribution than in males, which results in greater peak concentrations from the same dosage [13]. Polar medications are water-soluble, disperse through the bloodstream, and are initially removed by the kidneys. Lipids are soluble in non-polar medicines. Usually, the central nervous system, tissue, and fat are where these medications are distributed. Drugs are first removed from the body through bile and feces. Blood flow to the site of medication administration and throughout the body, as well as protein binding, are both necessary for this. A medicine can no longer have an impact on the body if it binds to a protein. The amount of a medicine that is accessible for distribution decreases in direct proportion to how much of it binds to protein [32]. The medication may then disperse into the interstitial and intracellular fluids after being absorbed and reversibly leaving the circulation. The blood-brain, blood-test, and blood-placenta barriers can be used to explain a drug's permeability. Blood flow, lipophilicity, molecular size, and the drug's interactions with blood components such plasma proteins are a few variables that may have an impact on this. For instance, a medication like warfarin is largely protein-bound, which implies that only a tiny portion of the medication is available to work therapeutically in the circulation. If warfarin is administered together with a medication that is heavily protein-bound, it may push warfarin out of the protein-binding site and increase the amount that enters the circulation. Additionally, certain organs have anatomical barriers, such as the blood-brain barrier, which prevent some medications from penetrating brain tissue. The blood brain barrier will be more easily crossed by medications with specific properties, such as high lipophilicity, small size, and molecular weight. The majority of medications is to some extent protein-bound; only an unbound medication is free to perform its pharmacological activity(s). Depot storage applies to pharmaceuticals that bind to calcium and other substances that are lipophilic and store in fat. Protein + medication (free

This article is a preprint and has not been certified by peer review

to perform pharmacological action(s)), protein + medicine (complex that is inactive), and medicine + plasma protein [33].

Protein Binding: A medication may be free or protein-bound in the body. Only free drugs are able to pass into other fluid compartments, function at their pharmacologically active locations like receptors, or be eliminated. More closely associated with effect than plasma total concentration is the free concentration of a medication at receptor sites. Any decrease in plasma protein binding increases the quantity of medication that may act on receptors, potentially having a stronger impact or increasing the risk of toxicity. Albumin and alpha-acid glycoprotein are the main proteins in charge of binding relevant medications [34]. Highly protein-bound medications might be competitively replaced by another medication that is also highly protein-bound. The displaced drug's pharmacologic action will increase, as will renal clearance. The concentration of free drug will be higher in illness states defined by hypoalbuminemia and lower in disease conditions characterized by elevated acute phase proteins (A1AG). As a result, the relationship between the drug's pharmacological action and its free (unbound) concentration in blood is linear. A strongly bound medication may be displaced by endogenous compounds (bilirubin, fatty acids), and in certain people with renal illness, without hypoalbuminemia, binding may decrease owing to changes in albumin's protein charges. Although there does not appear to be a persistent sex difference in albumin levels, endogenous estrogens cause a reduction in the plasma levels of AAG, resulting in lower amounts of AAG in women than in males. Exogenous estrogens raise serum-binding globulin [35].

6. Metabolism or Biotransformation

The body converting a medication into subsequent substances is known as metabolism. In the event of prodrug delivery, such as with codeine, metabolism may be required to transform the drug into active metabolites [36]. In general, metabolism can function to transform the drug into more water-soluble molecules that will advance to renal clearance. The process of converting generally more lipophilic xenobiotic substances into hydrophilic metabolites, abolishing the pharmacological effects of drugs (to determine how long they will last), converting prodrugs into active parent drugs, converting active drugs into more active metabolites (which lengthens the duration of their effects), turning drugs into toxic metabolites, and turning drugs into chains of active drugs (such as diazepam) that can be excreted from the body through excretion are The (prodrug) activity of metabolites compared to the parent drug might vary. Cytochrome enzymes (P450 enzymes) are mostly produced by the liver, while they may also be found in the gastrointestinal tract, heart, lungs, brain, and kidneys.

- **Phase I reactions (nonsynthetic):** Phase I processes, which are nonsynthetic, include oxidation, reduction, or hydrolysis of the parent structure to produce smaller, more water-soluble metabolites. The cytochrome P450 enzymes handle them in a dominant manner. Phase I processes, which modify chemical structure by oxidation, reduction, or hydrolysis to create a more polar molecule for elimination, can break down drug molecules. In metabolism, the cytochrome P-450 enzyme system is crucial. Phase I reactions sometimes serve as a "handle" for later Phase II reactions to carry out further changes [37].
- **Phase II reactions (synthetic):** Phase II processes (synthetic) may involve the coupling of a chemical (parent substance and/or phase I metabolite) to a water-soluble endogenous molecule to aid excretion, such as glutathione, glucuronic acid, or sulfate. In phase II processes, enzymes can also break down drugs into water-soluble forms by conjugating them with

This article is a preprint and has not been certified by peer review

glutathione, glucuronide, sulfate, methyl- and acetyl-groups.

Pharmacokinetics, particularly metabolic ones, are the most prevalent causes of interactions between medications. As cytochrome P450 interactions, they are. Many clinically significant interactions result from substrate inhibition or induction (medicines that are importantly metabolised by the given enzymes). Compounds known as inhibitors are frequently able to stop the metabolism of certain substrates. When the inhibitor is administered, the plasma concentration of the substrate may increase. For example, ciprofloxacin inhibits the CYP3A4 enzyme that metabolizes clozapine, which may impact clozapine toxicity by reducing enzyme production and clozapine metabolism. Ciprofloxacin also increases clozapine plasma levels, and in the end, ciprofloxacin causes clozapine toxicity. The stated enzyme's activity can be accelerated by inducers of the specific P450, which lowers the plasma concentrations of the listed substrates. For instance, carbamazepine starts the cyclosporin metabolism through the CYP3A4 enzyme, influencing to a reduction in plasma levels of cyclosporin and hence loss of efficacy by elevating enzyme generation and metabolism of cyclosporin, carbamazepine lower the plasma level concentration of cyclosporin, then carbamazepine failurity.

Statins, or anti-cholesterol medications, and grapefruit juice need the same enzyme in the liver to be metabolized and will compete with one another for it. Because of this, statin users should refrain from mixing their medication with grapefruit juice. There are various variables that influence how quickly or slowly a person metabolizes medicines, including genetics. Liver function can change with age; older people have decreased liver function and may metabolize medications more slowly, which increases the risk of intolerance; neonates and babies have immature liver functions and may require particular dose considerations. Sex, females are not as capable of metabolizing some medications as males. For example, males have larger stomach levels of alcohol dehydrogenase than females, which prevents females from easily metabolizing alcohol, but intestine CYP3A4 levels are not consistently sex-specific. Drug interactions may cause a drug's metabolism to be decreased by inhibiting an enzyme or increased by inducing an enzyme. Genetic differences in CYP2D6, the mechanism through which codeine is metabolized, can have significant clinical impact. CYP2D6 poor metabolizers (PMs) frequently have greater blood concentrations of active medications. PMs have increased blood levels of the ineffective substance in codeine, which may lead to inefficiency. In contrast, individuals with ultra-rapid metabolisms (UMs) will convert codeine to morphine very quickly, resulting in hazardous morphine levels (Figure 4).

a preprint and has not been certified by peer review



Fig. 4 Mechanism by which ultra-rapid metabolizers transform codeine (inactive) to morphine (active).

7. Excretion

The process by which a substance is expelled from the body is known as excretion. The kidneys are most often the site of excretion, however with some medications, the lungs, skin, or GIT may also be involved. Drug clearance in the kidneys can occur by passive filtration in the glomerulus or secretion in the

tubules, however this process can be complicated by compound reabsorption [38]. The permanent removal of a material from the body is known as excretion. Every drug-related substance, including the parent drug and its metabolites, is eventually eliminated from the body. Drugs that are lipid soluble or lipophilic can be eliminated by sweat (for lipid soluble or lipophilic drugs), tears, or breath, however these methods are less prevalent. Some non-polar medications that are lipid soluble are eliminated through the skin or sweat glands without being metabolized. Non-polar medications are excreted in the same manner [10]. The lungs (for volatile/gaseous medications), intestines, kidney, and bile can all be used by the body to expel drugs or substances (for large molecular size medicines). However, the majority of water-soluble medicines or metabolites are mostly eliminated by renal excretion. The apparent $t_{1/2}$ of the parent chemical or its active metabolite may be significantly impacted by changes in renal function, as well as the molecule's clearance(s). For instance, decreased renal function will result in an increase in serum drug concentrations over time while the medication is being provided, which may speed up the pharmacological effects of the medication [39]. Numerous variables, such as direct renal impairment, might impact excretion, extending certain medications' half-lives and requiring dosage modifications. Drug excretion may be less effective due to aging, which can affect drug dosage and excretion rates, as well as diseases that affect renal blood flow, such as congestive heart failure and liver disease.

8. Key Pharmacokinetic Parameters

Half-Life: Half-life ($t_{1/2}$) is the amount of time needed for the body to remove half of the initial dose of a medication. The substance is deemed undetectable and unable to exert a pharmacodynamic impact after three to five $t_{1/2}$ [40]. That is, $t_{1/2}$ = 0.693/ke, where ke is the drug's first order elimination constant. For example, 25% of a medicine dose with a half-life of 12 hours would still be present in the body after 24 hours. Many drugs are categorized according to their half-lives. For example, the benzodiazepines are categorized according to: Midazolam and triazolam are ultra-short acting ($t_{1/2}$ 6 hours), oxazepam and temazepam are short acting ($t_{1/2}$ 6–12 hrs), while alprazolam, bromazepam, and lorazepam are medium acting ($t_{1/2}$ 12–24 hrs). Long-acting ($t_{1/2}$ > 24 hrs): 50% reduction in drug levels in the body for clobazepam, clonazepam, diazepam, flunitrazepam, and nitrazepam. The time it takes for medication concentrations to reach half (or 50%) of the anticipated steady-state concentration when a drug is given in repeated doses or as a zero-order infusion is also represented by $t_{1/2}$. $T_{1/2}$ = volume/ CL *(0.693) [40] provides a good approximation of the link between the clinically relevant $t_{1/2}$, clearance, and volume of distribution.

Apparent volume of distribution: The apparent volume of distribution is a pharmacokinetic parameter used to describe the pattern of drug distribution in plasma and in various tissues, as well as the size of the compartment into which a drug would seem to have dispersed in response to its concentration in plasma (Vd). It is frequently expressed as liters per kilogram (L/kg) and determined by measuring the peak plasma drug concentrations for an IV-administered medication after the distribution has stabilized. Vd = dosage/plasma drug concentration compares that concentration to the IV dose administered (PDC).The apparent volume to which phenobarbital is dispersed (Vd) = (12 mg/kg / 20 mg/L) = 0.6 L/kg, for example, if phenobarbital is administered at a dose of 12 mg/kg and the sequencing PDC after distribution has taken place is 20 mg/L [41]. The Vd can be impacted by a number of clinically significant factors, including age (larger in neonates and pediatrics, smaller in geriatrics), fluid accumulations, plasma protein concentration (leading unbound drug only), acid-base status (especially if ion trapping causes the drug to accumulate in tissues), inflammatory processes or

This article is a preprint and has not been certified by peer review

necrosis, and any other causes for alteration. Drug distribution to muscles and skin will take anywhere between minutes and hours. The time it takes for medications to reach fat storage might range from hours to days. The drawbacks of Vd are that it cannot predict real locations of distribution and may depend on total body water (0.65 L/kg). Furthermore, medication distribution must be comprehensive in order for individual variations in protein binding or tissue binding to be accounted for. Drug quantity/concentration = volume of distribution. A huge volume of distribution frequently means that the medicine has a significant effect on bodily fluids and tissues. In contrast, a low volume of distribution frequently denotes insufficient medication delivery. Although the tissues or fluids into which the medication spreads are not shown by volume of distribution, it does reflect the extent of dissemination. Although the volume of distribution of two medications may be equal, one drug may initially diffuse into muscle tissues while the other may concentrate in adipose tissues [33].

Drug clearance: The amount of blood from which a medication is permanently removed, or cleared, is referred to as clearance. Although plasma is most usually collected, plasma clearance really represents the total of all organ clearances. If just one organ is responsible for the drug's clearance, that organ's clearance is measured by plasma clearance. Clearance is measured in volume/mass/time (for instance, mL/kg/min) since it is a volume. If the elimination rate constant is known, it will explain the portion of the volume of distribution (Vd) cleared, and together they can be used to calculate clearance (CL) from the plasma drug concentration vs. time curve: CL = Vdke/time. Clearance is also defined as the volume of plasma that would contain the amount of drug excreted per unit time (min). As a result, much like Vd, CL has a direct impact on ke, or the rate at which drugs are excreted from the body; as CL rises, ke steepens. No matter how much of a drug is in the blood, the same amount will be removed per unit time regardless of the drug's Vd and, consequently, its concentration. The relative clearance by each organ is calculated by dividing the rate of elimination for each organ by a drug concentration (for instance, the systemic concentration). Other possible routes of elimination include partition into the intestine, presence in saliva or perspiration, and metabolism at locations other than the liver (for example, nitroglycerin, which is processed in all bodily tissues) [32].

Elimination Rate Constant: The elimination rate constant, ke, which is the slope of the terminal, or elimination, component of the PDC *vs.* time curve, is used to calculate elimination half-life. Ke is a "hybrid" parameter whose effects are influenced by both CL and Vd. The larger the amount of medication removed, the steeper the slope, or ke, since CL determines the drop in PDC. A greater Vd indicates less drug is in the volume of blood cleared by the liver or kidneys, which has an impact on $t_{1/2}$ as it does on plasma drug concentration. As a result, there is an inverse connection between the rate of elimination and Vd. A drug's elimination half-life ($t_{1/2}$) is the amount of time that passes after PDC falls by 50%. The following formula is used to determine it: $t_{1/2}$ = 0.693/ke. The link between kel and $t_{1/2}$ reflects the fact that when C1 drops by 50% (i.e., C1/C2 = 2), $t_{1/2}$ becomes run of the slope (t2-t1). Since $t_{1/2}$ is the inverse of kel and the natural log of 2 is equal to 0.693, $t_{1/2}$ is directly related to Vd (a higher Vd leads in a longer $t_{1/2}$) and inversely proportional to CL. Note that whereas $t_{1/2}$ may not vary, CL and Vd might undergo significant alteration. For instance, CL can drop by 50% in a dehydrated animal with renal impairment, tripling $t_{1/2}$. However, if the animal is significantly dehydrated, Vd will decrease as a result of the volume of extracellular fluid contracting. Because the kidney may remove more medications per milliliter of blood, the same amount of drugs may be removed, and as a result, ke or $t_{1/2}$ may not change. The time to steady-state (see

This article is a preprint and has not been certified by peer review

below) and the amount of time it takes for a medication to leave the body after use has stopped are determined by the elimination $t_{1/2}$. For practical purposes, the majority of medicines are gone within 3-5 $t_{1/2}$ [32].

Kinetic models: The kinetics of metabolism might be first-order, zero-order, or nonlinear. When the amount of medicine removed depends on the compound's concentration and follows a logarithmic relationship over time, this is referred to as first-order kinetics. With dosage or concentration, there is no change in the clearance or Vd. When the rate of elimination is independent of the drug concentration, this is known as zero-order kinetics. Drugs like ethanol, phenytoin, and salicylates exhibit zero-order kinetics at high doses. Depending on the saturation of the elimination processes, capacity-limited or nonlinear kinetics occurs when the rate of elimination changes from first-order to zero-order. Importantly, any medication may have capacity limitations as a result of an overdose [42].

Rates of reaction: The rates of kinetics processes, which may be characterized by two fundamental underlying principles, must be taken into account in order to analyze the processes of ADME. The velocity at which a reaction or process occurs may be used to characterize its rate, which can be either zero-order or first-order.

Zero-order reaction: Take into account how quickly medication "A" is excreted from the body. The rate of elimination of the medication "A" can be expressed as: $dA/dt = k$, where k is the zero-order rate constant, if the quantity of the drug is decreasing at a constant pace. The pace of the reaction is constant and unaffected by the body's concentration of "A". Eliminating alcohol is one example. Drugs with this kind of elimination will accumulate in the plasma, leading to nonlinear pharmacokinetics.

First-order reaction: The rate of drug "A" elimination may be expressed as: $dA/dt = KA$, where k is the first-order rate constant, if the quantity of drug "A" is decreasing at a rate that is proportional to "A", the amount of drug "A" left in the body. The amount of "A" present in the body affects how quickly the response happens. First-order responses are thought to govern ADME processes, and this is also how most medicines are removed. The majority of medications used in clinical settings at therapeutic doses exhibit first-order rate processes, meaning that their rates of elimination are typically first-order. There are important exceptions, such as high-dose salicylates and phenytoin. In summary, one may demonstrate that, when the dosage of a medication is increased, the body is able to clear the drug appropriately, preventing buildup for substances with a first-order elimination mechanism. The plasma concentration will double with a dosage increase. However, if you keep increasing the dosage of the medication being supplied, all medicines will change from displaying a first-order to a zero-order process, as in an overdose scenario [42].

9. Conclusions

Pharmacokinetics, which describes the flow of a drug into, through, and out of the body as well as the timing of its absorption, bioavailability, distribution, metabolism, and excretion, can occasionally be defined as what the body does to a medication. The process of releasing a medication from the pharmaceutical formulation is known as liberation. A medicine's pharmacokinetics is determined by characteristics specific to the patient as well as by the chemical makeup of the drug. Absorption affects how quickly and how concentratedly a medication may reach the desired site of action, such as plasma. Liberation, or the process by which the medication is freed from its pharmaceutical dosage form, is frequently a part of the absorption process. The process of metabolism involves changing often more lipophilic xenobiotic substances into hydrophilic metabolites that may be excreted from the body. The apparent volume of distribution is a pharmacokinetic

This article is a preprint and has not been certified by peer review

term used to describe the pattern of a drug's distribution in plasma and in various tissues, as well as the size of the compartment into which a drug would seem to have dispersed in proportion to its concentration in plasma.

Acknowledgement

The author would be appreciative of anonymous reviewers' suggestions that might improve this paper.

Data Sources

Google Scholar, Research Gate, PubMed, NCBI, NDSS, PMID, PMCID, Scopus database, SciELO, and Cochrane database are only a few of the sources that were looked up (Included in the search terms about pharmacokinetics).

Funding

None.

Conflict of Interest

The author has no financial or proprietary interest in any of material discussed in this article.

References

[1] Ahammad, F., Alam, R., Mahmud, R., et al. 2021. "Pharmacoinformatics and Molecular Dynamics Simulation-based Phytochemical screening of Neem Plant (*Azadiractha indica*) against Human Cancer by Targeting MCM7 Protein." *Brief Bioinform* 22 (5): bbab098. doi: 10.1093/bib/bbab098.

[2] Feghali, M., Venkataramanan, R., and Caritis, S. 2015. "Pharmacokinetics of Drugs in Pregnancy." *Semin Perinatol* 39 (7): 512-9.

[3] Vrbanac, J., and Slauter, R. 2017. "ADME in Drug Discovery." *A Comprehensive Guide to Toxicology in Nonclinical Drug Development (Second Edition)* pp. 39-67.

[4] Saghir, S. A., and Ansari, R. A. 2018. "Pharmacokinetics." in Reference Module in Biomedical Sciences, 2018.

[5] Bisswanger, H. 2017. "Enzyme Kinetics: Principles and Methods." John Wiley & Sons.

[6] Shanbhag, T. V., Shenoy, S., and Nayak, V. 2021. "Pharmacology for Dentistry" eBook ISBN: 9788131238844.

[7] Holford, N., Ma, G., and Metz, D. 2020. "TDM is Dead. Long Live TCI!" *Br J Clin Pharmacol* doi: 10.1111/bcp.14434.

[8] Waller, D. G., and Sampson, A. P. 2018. *Medical Pharmacology and Therapeutics* (Fifth Edition).

[9] Soldin, O. P., and Mattison, D. R. 2009. "Sex Differences in Pharmacokinetics and Pharmacodynamics." *Clin Pharmacokinet* 48 (3): 143-57.

[10] Loftsson, T. 2015. "Physicochemical Properties and Pharmacokinetics." In book: *Essential Pharmacokinetics*, pp. 85-104.

[11] Parkinson, A., Ogilvie, B. W., Buckley, D. B., et al. 2018. "Chapter 6: Biotransformation of Xenobiotics". In the book: Casarett & Doull's Toxicology: The Basic Science of Poisons, 9th edition. pp. 194.

[12] McKenna, M. J. 2020. "The Role of Studies of Absorption, Metabolism, Distribution and Elimination in Animal Selection and Extrapolation." In *Human Risk Assessment—the Role of Animal Selection and Extrapolation* (pp. 113-128). CRC Press.

[13] Slørdal, L., and Spigset, O. 2005. "Basic Pharmacokinetics--Distribution" (Article in Norwegian) *Tidsskr Nor Laegeforen* 125 (8): 1007-8.

[14] Kalyane, D., Raval, N., Maheshwari, R., et al. 2019. "Employment of Enhanced Permeability and Retention Effect (EPR): Nanoparticle-based Precision Tools for Targeting of Therapeutic and Diagnostic Agent in Cancer." *Mater Sci Eng C Mater Biol Appl* 98: 1252-76.

[15] Abuhelwa, A. Y., Williams, D. B., Upton, R. N., & Foster, D. J. R. 2017. "Food, Gastrointestinal pH, and Models of Oral Drug Absorption." *Eur J Pharm Biopharm* 112: 234-48.

[16] Yadav, A., and Mohite, S. 2020. "Recent Advances in Protein and Peptide Drug Delivery." *Res. J. Pharma. Dosage Forms and Tech* 12 (3): 205-212.

[17] Sebastiano, M. R., Doak, B. C., Backlund, M., et al. 2018. "Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs beyond the Rule of 5." *J Med Chem* 61 (9): 4189-202.

[18] Luan, X., Zhang, L. J., Li, X. Q., et al. 2020. "Compound-based Chinese Medicine Formula: From Discovery to Compatibility Mechanism." *J Ethnopharmacol* 254: 112687. doi: 10.1016/j.jep.2020.112687.

[19] Min, K. A., and Rosania, G. R. 2021. "Measurement of Transcellular Transport Rates and Intracellular Drug Sequestration in the Presence of an Extracellular Concentration Gradient." In *Quantitative Analysis of Cellular Drug Transport, Disposition, and Delivery* pp. 3-39.

[20] Behl, T., Kaur, I., Sehgal, A., et al. 2021. "The Interplay

This article has been certified by peer review and has not been published

of ABC Transporters in Aβ Translocation and Cholesterol Metabolism: Implicating Their Roles in Alzheimer's Disease." *Mol Neurobiol* 58 (4): 1564-82.

[21] Vasiliou, V., Vasiliou, K., and Nebert, D. W. 2009. "Human ATP-binding Cassette (ABC) Transporter Family." *Hum Genomics* 3 (3): 281-90.

[22] Saunders, N. R., Habgood, M. D., Møllgård, K., & Dziegielewska, K. M. 2016. "The Biological Significance of Brain Barrier Mechanisms: Help or Hindrance in Drug Delivery to the Central Nervous System?" *F1000Res* doi: 10.12688/f1000research.7378.1.

[23] Shan, N., Perry, M. L., Weyna, D. R., & Zaworotko, M. J. 2014. "Impact of Pharmaceutical Cocrystals: the Effects on Drug Pharmacokinetics." *Expert Opin Drug Metab Toxicol* 10 (9): 1255-71.

[24] Batchelor, H. K., and Marriott, J. F. 2015. "Formulations for Children: Problems and Solutions." *Br J Clin Pharmacol* 79 (3): 405-18.

[25] Williams, A. C. 2018. "Topical and Transdermal Drug Delivery." In the *Aulton's Pharmaceutics: the Design and Manufacture of Medicines*. 5th ed. Edinburgh: Elsevier. pp. 715-38.

[26] Johnson, A. R., Forster, S. P., White, D., et al. 2021. "Drug Eluting Implants in Pharmaceutical Development and Clinical Practice." *Expert Opin Drug Deliv* 18 (5): 577-593.

[27] Pavlović, N., Goločorbin-Kon, S., Đanić, M., et al. 2018. "Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles." *Front Pharmacol* 9: 1283.

[28] Bardal, S. K., Waechter, J. E., & Martin, D. S. 2011. *Applied Pharmacology*. Elsevier/SaundersSt. Louis, Mo.©2011.

[29] Kisitu, J., Hollert, H., Fisher, C., & Leist, M. 2020. "Chemical Concentrations in Cell Culture Compartments (C5)–Free Concentrations." *ALTEX* 37 (4): 693-708.

[30] Starkey, E. S., and Sammons, H. M. 2015. "Practical pharmacokinetics: what do you really need to know?" *Arch Dis Child Educ Pract Ed* 100 (1): 37-43.

[31] Gupta, S., Kesarla, R., and Omri, A. 2013. "Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-emulsifying Systems." *ISRN Pharm* doi: 10.1155/2013/848043.

[32] Khan, M. S., and Roberts, M. S. 2018. "Challenges and Innovations of Drug Delivery in Older Age." *Adv Drug Deliv Rev* 135: 3-38.

[33] Wanat, K. 2020. "Biological Barriers, and the Influence of Protein Binding on the Passage of Drugs across Them." *Mol Biol Rep* 47 (4): 3221-31.

[34] Mei, H., Wang, J., Che, H., et al. 2019. "The Clinical Efficacy and Safety of Vancomycin Loading Dose: A Systematic Review and Meta-analysis." *Medicine (Baltimore)* 98 (43): e17639.

[35] Tripathi, K. D. 2013. "Essentials of Medical Pharmacology." Available on: https://pharmacyfunblog.files.wordpress.com/2016/11/kd-tripathi-essentials-of-medical-pharmacologyunitedvrg-2013.pdf.

[36] Alcorn, J., and McNamara, P. J. 2003. "Pharmacokinetics in the Newborn." *Adv Drug Deliv Rev* 55 (5): 667-86.

[37] Taxak, N., and Bharatam, P. V. 2014. "Drug metabolism: A Fascinating Link between Chemistry and Biology." *Resonance – Journal of Science Education* 19 (3): 259-82.

[38] Su, C., Liu, Y., Li, R., et al. 2019. "Absorption, Distribution, Metabolism and Excretion of the Biomaterials Used in Nanocarrier Drug Delivery Systems." *Adv Drug Deliv Rev* 143: 97-114.

[39] Kok-Yong, S., and Lawrence, L. 2015. "Drug Distribution and Drug Elimination." *Basic Pharmacokinetic Concepts and Some Clinical Applications* DOI: 10.5772/59929. Available from: https://www.intechopen.com/chapters/48275.

[40] Nakamura, G., Ozeki, K., Nagayasu, M., et al. 2020. "Predicting Method for the Human Plasma Concentration–Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates." *Biol Pharm Bull* 43 (5): 823-30.

[41] van den Anker, J., Reed, M. D., Allegaert, K., & Kearns, G. L. 2018. "Developmental Changes in Pharmacokinetics and Pharmacodynamics." *J Clin Pharmacol* 58 Suppl 10: S10-S25.

[42] Bardal, S. K., Waechter, J. E, & Martin, D. S. 2011. *Applied Pharmacology* Elsevier/Saunders St. Louis, Mo.©2011.

This is a pre-print and has not been reviewed by